Upgrade to SI Premium - Free Trial

Summit Therapeutics (SMMT)

17.59 +0.42 (2.45%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/11/26)

Latest Headlines

Form PRE 14A Summit Therapeutics Inc. For: Oct 06 October 6, 2026 5:04 PM - SEC Filing Bernstein SocGen: 'We still think investors should not be long Summit Therapeutics plc (SMMT)' October 5, 2026 8:19 AM - StreetInsider AstraZeneca closes $2 billion equity stake in Summit Therapeutics October 5, 2026 7:01 AM - StreetInsider AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics October 5, 2026 7:00 AM - BizWire Summit Therapeutics to test ivonescimab with AstraZeneca-Daiichi ADC October 2, 2026 6:04 AM - StreetInsider AstraZeneca (AZN) Daiichi Sankyo, AstraZeneca, and Summit to trial Datroway combo October 2, 2026 2:46 AM - StreetInsider Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types October 2, 2026 2:30 AM - BizWire Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway October 2, 2026 2:30 AM - BizWire Summit Therapeutics plc (SMMT) PT Raised to $20 at Barclays October 1, 2026 4:00 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) September 30, 2026 7:10 AM - StreetInsider Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens as AZN Invests $2B in Strategic Equity September 30, 2026 4:34 AM - StreetInsider High-Stakes October has these Biotechs Entering Crucial Stretch September 29, 2026 12:13 PM - StreetInsider Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald September 29, 2026 7:16 AM - StreetInsider Form 8-K Summit Therapeutics Inc. For: Sep 28 September 29, 2026 6:05 AM - SEC Filing Goldman Sachs Reiterates Buy Rating on Summit Therapeutics plc (SMMT) September 29, 2026 5:38 AM - StreetInsider Summit Therapeutics plc (SMMT) PT Raised to $30 at Jefferies September 29, 2026 5:16 AM - StreetInsider Stifel Reiterates Buy Rating on Summit Therapeutics plc (SMMT) September 29, 2026 5:14 AM - StreetInsider Summit Therapeutics gets $2B AstraZeneca investment, Citi raises target September 29, 2026 5:03 AM - StreetInsider AstraZeneca invests $2B in Summit Therapeutics preferred shares September 28, 2026 5:33 PM - StreetInsider AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics September 28, 2026 5:30 PM - BizWire Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens September 25, 2026 4:17 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) September 23, 2026 6:51 AM - StreetInsider Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald September 22, 2026 7:47 AM - StreetInsider Ivonescimab trial data in biliary tract cancer to be shown at ESMO 2026 September 22, 2026 6:01 AM - StreetInsider HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be September 22, 2026 6:00 AM - BizWire UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT) September 16, 2026 8:47 AM - StreetInsider Form 8-K Summit Therapeutics Inc. For: Sep 15 September 15, 2026 8:45 AM - SEC Filing Summit ivonescimab shows consistent survival data across regions at WCLC September 15, 2026 6:01 AM - StreetInsider Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients September 15, 2026 6:00 AM - BizWire Form 8-K Summit Therapeutics Inc. For: Sep 13 September 14, 2026 8:38 AM - SEC Filing Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer September 13, 2026 7:47 PM - StreetInsider Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study September 13, 2026 7:00 AM - BizWire Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy September 9, 2026 6:45 AM - StreetInsider UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT) September 8, 2026 9:12 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) September 3, 2026 6:57 AM - StreetInsider Summit Therapeutics plc (SMMT) Reiterated at Overweight by Cantor Fitzgerald September 1, 2026 6:54 AM - StreetInsider Form 8-K Summit Therapeutics Inc. For: Aug 25 August 26, 2026 9:17 AM - SEC Filing Guggenheim Reiterates Buy Rating on Summit Therapeutics plc (SMMT) August 26, 2026 7:09 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) August 26, 2026 6:40 AM - StreetInsider Akeso's ivonescimab beats durvalumab in biliary tract cancer trial August 25, 2026 6:39 PM - StreetInsider Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Tria August 25, 2026 6:00 PM - BizWire Summit Therapeutics publishes HARMONi Phase III lung cancer trial data August 25, 2026 7:02 AM - StreetInsider Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology August 25, 2026 7:00 AM - BizWire Bernstein SocGen Group Upgrades Summit Therapeutics plc (SMMT) to Market Perform August 25, 2026 2:25 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) August 19, 2026 6:49 AM - StreetInsider China approves ivonescimab plus chemo for squamous NSCLC August 12, 2026 9:22 AM - StreetInsider Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer August 12, 2026 9:22 AM - BizWire Leerink Upgrades Summit Therapeutics plc (SMMT) to Market Perform August 12, 2026 6:34 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) August 6, 2026 6:55 AM - StreetInsider Form 8-K Summit Therapeutics Inc. For: Aug 05 August 5, 2026 7:32 AM - SEC Filing Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer August 5, 2026 7:00 AM - BizWire Summit Therapeutics (SMMT) spreader of 10K contracts of January 10 and 25 calls trade July 27, 2026 6:32 AM - StreetInsider Summit Therapeutics plc (SMMT) PT Lowered to $38 at Stifel, But 'Fundamental Conviction Intact' July 24, 2026 7:38 AM - StreetInsider Summit Therapeutics plc (SMMT) PT Lowered to $38 at Guggenheim July 24, 2026 6:59 AM - StreetInsider Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald After Q2 Results July 24, 2026 6:53 AM - StreetInsider Summit Therapeutics (SMMT) Reports In-Line Q2 EPS July 23, 2026 5:42 PM - StreetInsider Form 8-K Summit Therapeutics Inc. For: Jul 23 July 23, 2026 4:35 PM - SEC Filing Form 424B5 Summit Therapeutics Inc. July 23, 2026 4:34 PM - SEC Filing Summit Therapeutics: substantial doubt about our ability to continue as a going concern July 23, 2026 4:25 PM - StreetInsider Form 10-Q Summit Therapeutics Inc. For: Jun 30 July 23, 2026 4:09 PM - SEC Filing Form 8-K Summit Therapeutics Inc. For: Jul 23 July 23, 2026 4:08 PM - SEC Filing Summit Therapeutics posts Q2 loss, reports ivonescimab trial data July 23, 2026 4:06 PM - StreetInsider Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026 July 23, 2026 4:05 PM - BizWire H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) July 23, 2026 7:10 AM - StreetInsider Arcus and Summit team up to test kidney cancer drug combo July 22, 2026 4:30 PM - StreetInsider Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer July 22, 2026 4:30 PM - BizWire Form 8-K Summit Therapeutics Inc. For: Jul 22 July 22, 2026 7:11 AM - SEC Filing Summit ivonescimab shows OS hazard ratio of 0.76 in lung cancer trial July 22, 2026 6:30 AM - StreetInsider Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study July 22, 2026 6:30 AM - BizWire Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026 July 16, 2026 8:00 AM - BizWire H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) July 16, 2026 6:48 AM - StreetInsider H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT) July 15, 2026 7:37 AM - StreetInsider Summit Therapeutics sells antibiotic asset ridinilazole for up to $105M July 14, 2026 7:00 AM - StreetInsider Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc. July 14, 2026 7:00 AM - BizWire Full Article List